Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Dr José Baselga, MD, Ian Bradbury, PhD, Holger Eidtmann, MD, Serena Di Cosimo, MD, Evandro de Azambuja, MD, Claudia Aura, MD, Henry Gómez, MD, Phuong Dinh, MD, Karine Fauria, PhD, Veerle Van Dooren, MSc, Gursel Aktan, MD, Aron Goldhirsch, MD, Tsai-Wang Chang, MD, Zsolt Horváth, MD, Maria Coccia-Portugal, MD, Julien Domont, MD, Ling-Min Tseng, MD, Georg Kunz, MD, Joo Hyuk Sohn, MD, Vladimir Semiglazov, MD, Guillermo Lerzo, MD, Marketa Palacova, MD, Volodymyr Probachai, MD, Lajos Pusztai, DPhil, Michael Untch, PhD, Richard D Gelber, PhD, Martine Piccart-Gebhart, PhD, on behalf of the NeoALTTO Study Team
Manuscrito
The Lancet
2012
NeoALTTO
